Skip to content
Meta-analysis

Perioperative Biologic and Targeted DMARDs in Patients with Rheumatic Diseases Undergoing Orthopedic Surgery: A Systematic Review and Meta-Analysis.

2026 · Clinica Terapeutica · Vol 177 5, pp. 1242-1256 · 0 citations
Medicine

TL;DR

Perioperative continuation of bDMARDs and tsDMARDs increases infection risk but reduces disease flare, and management should be individualized, considering drug-specific risks, including biomarker suppression and thromboembolism.

View source

Similar papers

Review Open access Jan 2026

Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis

Highlights • Tofacitinib improved ASAS response in ankylosing spondylitis patients.• It ameliorated disease activity, physical function, and quality of life.• 5 mg dose and 16-week treatment showed most favorable efficacy trends.• Safety similar to placebo except for higher risk of upper respiratory infection.

Le Shen, K. Han, Lei Bo et al. · 0 citations
Open access Sep 2026

Predictors at diagnosis for initiation of biologic or targeted synthetic disease-modifying anti-rheumatic drugs in patients with spondyloarthritis and psoriatic arthritis

There is limited data on factors predicting the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) in Spondyloarthritis (SpA) and Psoriatic arthritis (PsA). The relative importance of objective inflammation and other patient factors in this context is unclear. A retr...

Mohaned Hameed, S. Exarchou, Ankita Sharma et al. · 0 citations
Review Sep 2026

Biologic Therapies in Thyroid Eye Disease: A PRISMA-Based Systematic Review and Meta-Analysis of Clinical Outcomes, Safety Profiles and Impact on Surgical Management

Background: Biologic therapies have transformed Thyroid Eye Disease (TED) management, but their comparative efficacy, safety, durability and effects on subsequent rehabilitative surgery remain uncertain. Objective: To evaluate the efficacy and safety of teprotumumab, rituximab and tocilizumab across TED phenotypes and...

N. Yadav, S. Kundan, Swati Singh et al. · 0 citations
Review Open access Oct 2026

Temporal Patterns of Outcomes After DMARD Tapering or Withdrawal in Rheumatoid Arthritis With Sustained Disease Control: A Systematic Review and Meta‐Analysis

Rheumatoid arthritis (RA) requires lifelong treatment with disease‐modifying antirheumatic drugs (DMARDs). In patients with sustained disease control, DMARD de‐escalation has been proposed to lessen treatment burden, but its efficacy and safety remain elusive. We conducted a systematic review and meta‐analysis of rando...

Xiao-Yan Zhang, R. K. Pandey, Xi Luo et al. · 0 citations
Review Open access Sep 2026

Safety and efficacy of microbiota-directed adjunctive therapy in acute pancreatitis: a systematic review and meta-analysis of prebiotics, probiotics, and synbiotics

Background Prebiotics, probiotics, and synbiotics have been proposed as adjunctive treatments for acute pancreatitis (AP), but their clinical efficacy and safety remain uncertain. We conducted a systematic review and meta-analysis to evaluate their effects on recovery-related, efficacy, and safety-critical outcomes in...

Ji Sun, Jun Zheng, Ye Shen · 0 citations
Review Open access Oct 2026

The effect of sequential antiresorptive therapy after denosumab discontinuation on fracture risk: a systematic review and meta-analysis

Discontinuation of denosumab (DMAb) causes a rapid rebound in bone turnover and increases the risk of multiple vertebral fractures. However, the optimal sequential antiresorptive strategy and its specific timing remain uncertain. We systematically searched PubMed, Embase, Web of Science, and Cochrane Libra...

Qi-Wen Bao, Xuan Tang, Han Miao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.